Optimization of Dosage Regimen of Rezafungin against <i>Candida spp. </i>Based on Pharmacokinetic/Pharmacodynamic Analysis
- 1 Department of Clinic Pharmacy, Affiliated of Chengde Medical College, Chengde, China
- 2 Department of Pharmacy, The Affiliated Hospital of Chengde Medical College, Chengde, China
Abstract
Invasive candidiasis was the most common nosocomial fungal infection with high morbidity and mortality, which is mainly occurring in immunodeficiency and critical patients. Echinocandins were recommended as first-line drugs for the treatment and prevention of invasive candidiasis. In our study, we aimed to optimize the dosage of Rezafungin against Candida spp. based on pharmacokinetic/pharmacodynamics (PK/PD) analysis. We collected the published data about pharmacokinetic parameters of rezafungin and the MIC distribution of Candida spp . on rezafungin . Monte Carlo simulation was used to calculate probability of target attainment and a cumulative fraction of response to assess the best dosing regimen. The optimal dosage regimen for C. albicans and C. glabrata was 50 mg IV, and the optimal dosage regimen for C. parapsilosis was 100 mg IV. Lastly, rezafungin has an excellent antifungal effect on C. albicans , C. glabrata and C. parapsilosis.
- Horn, D.L., Neofytos, D., Anaissie, E.J., et al. (2009) Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clinical Infectious Diseases, 48, 1695-1703. https://doi.org/10.1086/599039
- Sofjan, A.K., Mitchell, A., Shah, D.N., et al. (2018) Rezafungin (CD101), a Next-Generation Echinocandin: A Systematic Literature Review and Assessment of Possible Place in Therapy. Journal of Global Antimicrobial Resistance, 14, 58-64. https://doi.org/10.1016/j.jgar.2018.02.013
- Pappas, P.G., Kauffman, C.A., Andes, D., et al. (2009) Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 48, 503-535. https://doi.org/10.1086/596757
- Pappas, P.G., Kauffman, C.A., Andes, D.R., et al. (2016) Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62, 409-417. https://doi.org/10.1093/cid/civ1194
- Zhao, Y.N., Perez, W.B., Jiménez-Ortigosa, C., et al. (2016) CD101: A Novel Long-Acting Echinocandin. Cellular Microbiology, 18, 1185-1316. https://doi.org/10.1111/cmi.12640
- Sandison, T., Ong, V., Lee, J., et al. (2017) Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Antimicrobial Agents and Chemotherapy, 61, e01627-16. https://doi.org/10.1128/AAC.01627-16
- Miese, L., Lin, K.-Y. and Ong, V. (2019) Rezafungin Treatment in Mouse Models of Invasive Candidiasis and Aspergillosis: Insights on the PK/PD Pharmacometrics of Rezafungin Efficacy. Pharmacology Research & Perspectives, 7, e00546. https://doi.org/10.1002/prp2.546
- Berkow, E.L. and Lockhart, S.R. (2018) Activity of CD101, a Long-Acting Echinocandin, against Clinical Isolates of Candida auris. Diagnostic Microbiology and Infectious Disease, 90, 196-197. https://doi.org/10.1016/j.diagmicrobio.2017.10.021
- Lepak, A., Zhao, M. and Andes, D. (2018) Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrobial Agents and Chemotherapy, 62, e01572. https://doi.org/10.1128/AAC.01572-18
- ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03667690?cond=Rezafungin&draw=2&rank=2
- Lepak, A.J., Zhao, M., VanScoy, B., et al. (2018) Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design. Antimicrobial Agents and Chemotherapy, 62, e01572-18. https://doi.org/10.1128/AAC.02154-17